Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7959602 | 0.92 | BDKRB2 (0.77) | BDKRB2RORC | |
| SCHEMBL6953002 | 0.91 | BDKRB2 (0.74) | BDKRB2RORC | |
| SCHEMBL6796200 | 0.89 | BDKRB2 (0.76) | BDKRB2RORC | |
| SCHEMBL7812381 | 0.88 | BDKRB2 (0.71) | BDKRB2RORC | |
| SCHEMBL7812379 | 0.88 | BDKRB2 (0.71) | BDKRB2RORC | |
| SCHEMBL6952270 | 0.87 | BDKRB2 (0.81) | BDKRB2RORC | |
| SCHEMBL6946966 | 0.86 | BDKRB2 (0.79) | BDKRB2RORC | |
| SCHEMBL6949762 | 0.86 | BDKRB2 (0.81) | BDKRB2RORC | |
| SCHEMBL6948267 | 0.86 | BDKRB2 (0.71) | BDKRB2RORC | |
| SCHEMBL7818114 | 0.85 | BDKRB2 (0.86) | BDKRB2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6734306-B2 | USEFUL IN THE TREATMENT OF INFLAMMATION, ASTHMA, ALLERGIC RHINITIS, PAIN OR THE LIKE | PFIZER, INC. | 2004-05-11 | — | — | US | disclosed |
| US-20020128271-A1 | N-benzenesulfonyl l-proline compounds as bradykinin antagonists | PFIZER INC. | 2002-09-12 | — | — | US | disclosed |
| EP-1213289-A1 | N-benzenesulfonyl L-proline compounds as bradykinin antagonists | PFIZER INC. (US) | 2002-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128271-A1 | N-benzenesulfonyl l-proline compounds as bradykinin antagonists | BDKRB1, HRH2, BDKRB2 | BDKRB2 3/4885RORC 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.